Beigene Ltd Stock Price, News & Analysis

BioAtla and BeiGene have revised their global co-development agreement into a licensing agreement for BA3071, a conditionally active CTLA-4 antibody. BeiGene now holds exclusive global rights for clinical development and commercialization, receiving all profits after royalty payments to BioAtla. This amendment is expected to accelerate BA3071’s market potential and aligns with BioAtla's growth strategy, supporting the introduction of innovative oncology treatments. BA3071 is currently planned for Phase 1/2 trials to assess its efficacy in combination with BeiGene's tislelizumab.

BeiGene, Ltd. (NASDAQ: BGNE) reported significant advancements in business, highlighting a record quarterly product sales of approximately $66 million in Q2 2020. The approvals for tislelizumab and BRUKINSA in multiple indications across various regions underscore growth. The company raised approximately $2.07 billion in a direct offering, enabling further pipeline development. However, total revenue decreased to $65.64 million from $243.35 million year-over-year, largely due to loss of collaboration revenue and ABRAXANE sales suspension. R&D expenses surged to $285.97 million.

BeiGene, a biotechnology company, will showcase its anti-PD-1 antibody tislelizumab and PARP inhibitor pamiparib at the upcoming 2020 ESMO Virtual Congress from September 18-22. The company will present two mini oral presentations and five posters, highlighting significant clinical findings. Notable presentations include the clinical benefits of pamiparib in biomarker-positive patients and the efficacy of tislelizumab in various cancers. BeiGene aims to improve treatment outcomes and access through a diverse pipeline focused on oncology.

BeiGene announced that its New Drug Application (NDA) for pamiparib has received priority review status from the Center for Drug Evaluation (CDE) of the NMPA in China. Pamiparib is an investigational drug aimed at treating patients with BRCA-mutated advanced ovarian cancer who have undergone multiple chemotherapy lines. This marks BeiGene's third drug to achieve priority status in China. With over 1,200 patients enrolled in trials, pamiparib is also being explored in various solid tumors, indicating significant progress in biotechnology and cancer treatment advancement.

BeiGene has announced the acceptance of a new drug application (NDA) for pamiparib, an investigational PARP inhibitor, by the Center for Drug Evaluation in China. This NDA targets patients with deleterious or suspected deleterious BRCA-mutated advanced ovarian cancer treated with two or more chemotherapy lines. The application is backed by clinical data from a Phase 1/2 trial involving 113 patients. The company aims to offer new treatment options for this patient group and will present further clinical data soon.

BeiGene, a biotechnology company focused on cancer treatments, has successfully completed a direct offering of 145,838,979 ordinary shares at a price of $14.2308 per share, raising approximately $2.08 billion in gross proceeds. The offering, executed without an underwriter, allows BeiGene to enhance its financial position and further invest in its oncology pipeline.

The shares were provided under an automatically effective shelf registration statement previously filed with the SEC. This move signifies BeiGene's commitment to expanding its innovative cancer therapies.

BeiGene, a biotechnology company, announced a registered direct offering of 145,838,979 ordinary shares at $14.2308 each, resulting in approximately $2.08 billion in gross proceeds. The offering, made without underwriters, is set to close around July 15, 2020. Net proceeds, estimated at $2.07 billion after expenses, will be used for working capital and general corporate purposes. The offering is registered under an effective shelf registration statement filed with the SEC. Credit Suisse is advising on the offering.

BeiGene, a biotechnology company, announced the acceptance of a supplemental new drug application (sNDA) for its anti-PD-1 antibody, tislelizumab, to treat patients with previously treated unresectable hepatocellular carcinoma (HCC) in China. HCC is a prevalent type of liver cancer, especially in China, where unmet medical needs are significant. The sNDA is based on pivotal Phase 2 trial results involving 249 patients. The company aims to provide a viable treatment option for HCC patients, enhancing its oncology pipeline, which includes other ongoing trials for tislelizumab.

BeiGene has commenced the commercialization of XGEVA (denosumab) in China for treating giant cell tumor of bone (GCTB), marking a significant milestone in its strategic partnership with Amgen. XGEVA, approved by China's NMPA in May 2019, offers a novel therapy for GCTB, which typically requires surgical intervention. Clinical trials have shown promising results, with an 88% five-year progression-free survival rate. The company aims to leverage its extensive commercial organization to enhance patient access to innovative oncology treatments in China.